CVRx, Inc. Research and Development Expense
CVRx, Inc. (CVRX) reported Research and Development Expense of $3.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- CVRx, Inc. research and development expense for the quarter ending 2026-06-30 was $3.13M, a 26.77% increase year-over-year.
- CVRx, Inc. research and development expense for the quarter ending 2026-03-31 was $3.08M, a 22.53% increase year-over-year.
- CVRx, Inc. research and development expense for the quarter ending 2025-12-31 was $3.00M, a 6.95% increase year-over-year.
- CVRx, Inc. research and development expense for the quarter ending 2025-09-30 was $3.15M, a 25.64% increase year-over-year.
- CVRx, Inc. research and development expense for fiscal 2025 was $11.13M, a 0.01% increase from fiscal 2024.
- CVRx, Inc. research and development expense for fiscal 2024 was $11.13M, a 4.32% decline from fiscal 2023.
- CVRx, Inc. research and development expense for fiscal 2023 was $11.63M, a 16.89% increase from fiscal 2022.
- CVRx, Inc. research and development expense for fiscal 2022 was $9.95M, a 32.68% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.13M 10-Q · filed 2026-08-06 | $6.21M 10-Q · filed 2026-08-06 | $9.21M derived: sum of 3 quarters · filed 2026-08-06 | $12.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.08M 10-Q · filed 2026-05-12 | $6.08M derived: sum of 2 quarters · filed 2026-05-12 | $9.23M derived: sum of 3 quarters · filed 2026-05-12 | $11.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $6.15M derived: sum of 2 quarters · filed 2026-02-13 | $8.62M derived: sum of 3 quarters · filed 2026-08-06 | $11.13M 10-K · filed 2026-02-13 |
| 2025-09-30 | $3.15M 10-Q · filed 2025-11-06 | $5.62M derived: sum of 2 quarters · filed 2026-08-06 | $8.13M 10-Q · filed 2025-11-06 | $10.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.47M 10-Q · filed 2026-08-06 | $4.99M 10-Q · filed 2026-08-06 | $7.79M derived: sum of 3 quarters · filed 2026-08-06 | $10.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.52M 10-Q · filed 2026-05-12 | $5.32M derived: sum of 2 quarters · filed 2026-05-12 | $7.83M derived: sum of 3 quarters · filed 2026-05-12 | $10.59M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $5.31M derived: sum of 2 quarters · filed 2026-02-13 | $8.07M derived: sum of 3 quarters · filed 2026-02-13 | $11.13M 10-K · filed 2026-02-13 |
| 2024-09-30 | $2.50M 10-Q · filed 2025-11-06 | $5.27M derived: sum of 2 quarters · filed 2025-11-06 | $8.33M 10-Q · filed 2025-11-06 | $10.57M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.77M 10-Q · filed 2025-08-05 | $5.82M 10-Q · filed 2025-08-05 | $8.06M derived: sum of 3 quarters · filed 2025-08-05 | $10.76M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $3.06M 10-Q · filed 2025-05-09 | $5.30M derived: sum of 2 quarters · filed 2025-05-09 | $7.99M derived: sum of 3 quarters · filed 2025-05-09 | $11.27M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $4.94M derived: sum of 2 quarters · filed 2025-02-18 | $8.22M derived: sum of 3 quarters · filed 2025-02-18 | $11.63M 10-K · filed 2025-02-18 |
| 2023-09-30 | $2.70M 10-Q · filed 2024-11-01 | $5.98M derived: sum of 2 quarters · filed 2024-11-01 | $9.39M 10-Q · filed 2024-11-01 | $12.44M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $3.28M 10-Q · filed 2024-08-02 | $6.70M 10-Q · filed 2024-08-02 | $9.74M derived: sum of 3 quarters · filed 2024-08-02 | $12.04M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | $3.42M 10-Q · filed 2024-05-10 | $6.46M derived: sum of 2 quarters · filed 2024-05-10 | $8.76M derived: sum of 3 quarters · filed 2024-05-10 | $11.11M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $5.34M derived: sum of 2 quarters · filed 2024-02-09 | $7.69M derived: sum of 3 quarters · filed 2024-02-09 | $9.95M 10-K · filed 2024-02-09 |
| 2022-09-30 | $2.29M 10-Q · filed 2023-10-31 | $4.65M derived: sum of 2 quarters · filed 2023-10-31 | $6.91M 10-Q · filed 2023-10-31 | $8.70M derived: sum of 4 quarters · filed 2023-10-31 |
| 2022-06-30 | $2.35M 10-Q · filed 2023-08-03 | $4.61M 10-Q · filed 2023-08-03 | $6.41M derived: sum of 3 quarters · filed 2023-08-03 | $8.11M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $2.26M 10-Q · filed 2023-05-11 | $4.05M derived: sum of 2 quarters · filed 2023-05-11 | $5.75M derived: sum of 3 quarters · filed 2023-05-11 | $8.01M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $3.50M derived: sum of 2 quarters · filed 2023-02-10 | $5.75M derived: sum of 3 quarters · filed 2023-02-10 | $7.50M 10-K · filed 2023-02-10 |
| 2021-09-30 | $1.70M 10-Q · filed 2022-11-04 | $3.95M derived: sum of 2 quarters · filed 2022-11-04 | $5.70M 10-Q · filed 2022-11-04 | $6.21M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $2.25M 10-Q · filed 2022-08-01 | $4.00M 10-Q · filed 2022-08-01 | $4.51M derived: sum of 3 quarters · filed 2022-08-01 | $6.01M derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | $1.75M 10-Q · filed 2022-05-02 | $2.26M derived: sum of 2 quarters · filed 2022-05-02 | $3.76M derived: sum of 3 quarters · filed 2022-05-02 | $5.89M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $2.01M derived: sum of 2 quarters · filed 2022-02-22 | $4.14M derived: sum of 3 quarters · filed 2022-02-22 | $6.41M 10-K · filed 2022-02-22 |
| 2020-09-30 | $1.50M 10-Q · filed 2021-11-08 | $3.63M derived: sum of 2 quarters · filed 2021-11-08 | $5.90M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $2.13M 10-Q · filed 2021-08-09 | $4.40M 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |